| Bioactivity | DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer drugs (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component[1]. |
| Invitro | DC0-NH2(0-3 nM;72小时),在乳腺癌细胞系的活力测定实验中，对Ramos，Namalwa和HL60/s细胞具有很高的抗增殖效力，抑制 Namalwa 和 HL60/s 细胞增殖的 IC50值分别为 7 pM 和 5 pM，对 COLO205 细胞的抑制范围在 100 pM 之内[1]。 Cell Viability Assay[1] Cell Line: |
| Name | DC0-NH2 |
| CAS | 615538-51-7 |
| Formula | C31H24ClN5O3 |
| Molar Mass | 550.01 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
DC0-NH2
CAS: 615538-51-7 F: C31H24ClN5O3 W: 550.01
DC0-NH2 is an effector moiety for ADC and a simplified analog ofDC1 with better stability. DC0-NH2 is about 1000-fold mo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.